SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Clinuvel Pharmaceuticals Ltd
An SI Board Since December 2004
Posts SubjectMarks Bans Symbol
52 3 0 CLVLY
Emcee:  caly Type:  Moderated
Introduction Market Data Compact
Website: clinuvel.com

Investors page: clinuvel.com

Australian Exchange: finance.yahoo.com

ADR: finance.yahoo.com

pinksheets.com quote: pinksheets.com

Australian Message Board: sharescene.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
52CLVLY 26.15+7.50 (+40.21%) CLVLF 26.38+2.38 (+9.92%) CUV.AX 45.00+16.91 (+60caly110/9/2019
51CUV.AX up 60% in Australia on FDA approval announcement.caly-10/9/2019
50 CLVLY 19.85 0.85 4.47% CLVLF 19.61 0.65 3.43%caly-3/12/2019
49I quietly celebrate with myself. 14.76+1.50 (+11.31%)caly-8/31/2018
48Why no, we don't know why the stock is spiking.caly-10/31/2016
47There was an NBC news segment tonight that mentioned Scenesse, but not by name. caly-6/12/2015
46 European Commission approves SCENESSE Tuesday, 23 December 2014 10:38 Commcaly-12/22/2014
45Nice response to the news. 4.50 + 1.88 72%caly-10/27/2014
44Getting closer to approval in Europe. Friday, 24 October 2014 10:00Europe apprcaly-10/24/2014
43Even though the half-assed take over bid was rejected, the move has done wonderscaly-9/6/2014
42Clinuvel receives an unsolicited bid for the Company 27Jul2014 Clinuvel Pharmacaly-7/28/2014
41Clinuvel successful in US Phase III trial of SCENESSE® in rare skin disordecaly-11/10/2013
40Clinuvel commences US Phase III trial of SCENESSE® in rare light and UV discaly-5/22/2012
39Clinuvel, FDA agree in principle to Phase III study with SCENESSE® (afamelcaly-3/15/2012
38Clinuvel demonstrates positive treatment effect of afamelanotide in US Phase IIcaly-11/3/2011
37Clinuvel records first A$1 million in sales Successful first year of drug supplcaly-6/23/2011
36Letter to shareholders: clinuvel.comcaly-4/18/2011
35FDA allows Clinuvel’s innovative vitiligo trial facebook.comcaly-3/2/2011
34A clinical success: study retention rates clinuvel.comcaly-2/10/2011
33Clinuvel completes first Phase II US study Last patient visit completes confircaly-2/8/2011
32biotechnologynews.netcaly-1/11/2011
31Tuesday 16th November 2010 Melbourne, Australia TGA grants Orphan Drug Designatcaly-11/15/2010
30Company Announcement Tuesday 9th November 2010 Melbourne, Australia FDA providecaly-11/8/2010
29Interesting new potential application... clinuvel.com Company Announcement Wedcaly-8/25/2010
28Thanks for the heads-up. caly-7/13/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News